_version_ 1866915071020498944
author Dawood, Moez
Heavner, Ben
Wheeler, Marsha M.
Ungar, Rachel A.
LoTempio, Jonathan
Wiel, Laurens
Berger, Seth
Bernstein, Jonathan A.
Chong, Jessica X.
Délot, Emmanuèle C.
Eichler, Evan E.
Gibbs, Richard A.
Lupski, James R.
Shojaie, Ali
Talkowski, Michael E.
Wagner, Alex H.
Wei, Chia-Lin
Wellington, Christopher
Wheeler, Matthew T.
Members, GREGoR Partner
Carvalho, Claudia M. B.
Gifford, Casey A.
May, Susanne
Miller, Danny E.
Rehm, Heidi L.
Sedlazeck, Fritz J.
Vilain, Eric
O'Donnell-Luria, Anne
Posey, Jennifer E.
Chadwick, Lisa H.
Bamshad, Michael J.
Montgomery, Stephen B.
Diseases, Genomics Research to Elucidate the Genetics of Rare
Consortium
author_facet Dawood, Moez
Heavner, Ben
Wheeler, Marsha M.
Ungar, Rachel A.
LoTempio, Jonathan
Wiel, Laurens
Berger, Seth
Bernstein, Jonathan A.
Chong, Jessica X.
Délot, Emmanuèle C.
Eichler, Evan E.
Gibbs, Richard A.
Lupski, James R.
Shojaie, Ali
Talkowski, Michael E.
Wagner, Alex H.
Wei, Chia-Lin
Wellington, Christopher
Wheeler, Matthew T.
Members, GREGoR Partner
Carvalho, Claudia M. B.
Gifford, Casey A.
May, Susanne
Miller, Danny E.
Rehm, Heidi L.
Sedlazeck, Fritz J.
Vilain, Eric
O'Donnell-Luria, Anne
Posey, Jennifer E.
Chadwick, Lisa H.
Bamshad, Michael J.
Montgomery, Stephen B.
Diseases, Genomics Research to Elucidate the Genetics of Rare
Consortium
contents Rare diseases are collectively common, affecting approximately one in twenty individuals worldwide. In recent years, rapid progress has been made in rare disease diagnostics due to advances in DNA sequencing, development of new computational and experimental approaches to prioritize genes and genetic variants, and increased global exchange of clinical and genetic data. However, more than half of individuals suspected to have a rare disease lack a genetic diagnosis. The Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium was initiated to study thousands of challenging rare disease cases and families and apply, standardize, and evaluate emerging genomics technologies and analytics to accelerate their adoption in clinical practice. Further, all data generated, currently representing ~7500 individuals from ~3000 families, is rapidly made available to researchers worldwide via the Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) to catalyze global efforts to develop approaches for genetic diagnoses in rare diseases (https://gregorconsortium.org/data). The majority of these families have undergone prior clinical genetic testing but remained unsolved, with most being exome-negative. Here, we describe the collaborative research framework, datasets, and discoveries comprising GREGoR that will provide foundational resources and substrates for the future of rare disease genomics.
format Preprint
id arxiv_https___arxiv_org_abs_2412_14338
institution arXiv
publishDate 2024
record_format arxiv
spellingShingle GREGoR: Accelerating Genomics for Rare Diseases
Dawood, Moez
Heavner, Ben
Wheeler, Marsha M.
Ungar, Rachel A.
LoTempio, Jonathan
Wiel, Laurens
Berger, Seth
Bernstein, Jonathan A.
Chong, Jessica X.
Délot, Emmanuèle C.
Eichler, Evan E.
Gibbs, Richard A.
Lupski, James R.
Shojaie, Ali
Talkowski, Michael E.
Wagner, Alex H.
Wei, Chia-Lin
Wellington, Christopher
Wheeler, Matthew T.
Members, GREGoR Partner
Carvalho, Claudia M. B.
Gifford, Casey A.
May, Susanne
Miller, Danny E.
Rehm, Heidi L.
Sedlazeck, Fritz J.
Vilain, Eric
O'Donnell-Luria, Anne
Posey, Jennifer E.
Chadwick, Lisa H.
Bamshad, Michael J.
Montgomery, Stephen B.
Diseases, Genomics Research to Elucidate the Genetics of Rare
Consortium
Other Quantitative Biology
Rare diseases are collectively common, affecting approximately one in twenty individuals worldwide. In recent years, rapid progress has been made in rare disease diagnostics due to advances in DNA sequencing, development of new computational and experimental approaches to prioritize genes and genetic variants, and increased global exchange of clinical and genetic data. However, more than half of individuals suspected to have a rare disease lack a genetic diagnosis. The Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium was initiated to study thousands of challenging rare disease cases and families and apply, standardize, and evaluate emerging genomics technologies and analytics to accelerate their adoption in clinical practice. Further, all data generated, currently representing ~7500 individuals from ~3000 families, is rapidly made available to researchers worldwide via the Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) to catalyze global efforts to develop approaches for genetic diagnoses in rare diseases (https://gregorconsortium.org/data). The majority of these families have undergone prior clinical genetic testing but remained unsolved, with most being exome-negative. Here, we describe the collaborative research framework, datasets, and discoveries comprising GREGoR that will provide foundational resources and substrates for the future of rare disease genomics.
title GREGoR: Accelerating Genomics for Rare Diseases
topic Other Quantitative Biology
url https://arxiv.org/abs/2412.14338